Personalized medicine and opioid use disorder.  Kaya-Akyüzlü D.  World J Psychiatry. 2024 Sep 19;14(9):1285-1288. doi: 10.5498/wjp.v14.i9.1285. PMID: 39319227; PMCID: PMC11417659. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417659/

The epigenetic signatures of opioid addiction and physical dependence are prevented by D-cysteine ethyl ester and betaine.  McDonough J, Singhal NK, Getsy PM, Knies K, Knauss ZT, Mueller D, Bates JN, Damron DS, Lewis SJ.  Front Pharmac...

Effect of N-acetylcysteine on craving in substance use disorders (SUD): a meta-analysis of randomized controlled trials.  Cuocina M, Aiello G, Cutrufelli P, Rampello M, Rapisarda L, Rodolico A, Cantarella G, Signorelli MS, Bernardini R. ...

'You Can Die With Me But I Won't Let You Live With Me', Exploring Social Influences on the Continuation of Heroin Use in Men Who Use Heroin.  Houghton B, Kouimtsidis C, Duka T, Paloyelis Y, Bailey A, Notley C.  Subst Use. 2024 Sep 28;1...

Serum cytokines and inflammatory proteins in individuals with heroin use disorder: potential mechanistically based biomarkers for diagnosis.  Butelman ER, Huang Y, Cathomas F, Gaudreault PO, Roussos P, Russo SJ, Goldstein RZ, Alia-Klein N.&n...

Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.  Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. JAMA Netw Open. 2024 Sep 3;7(9):e2434704...